Effects of co-administration of amitriptyline and fluoxetine on inhibitory avoidance in mice. 2010

Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
Department of Psychobiology, University of Valencia, Valencia, Spain. andres.parra@uv.es

We have previously observed that, while the impairing effects of amitriptyline on inhibitory avoidance in mice are consistently observed, those of acute fluoxetine are negligible. Two experiments were designed to investigate whether a regular dose of fluoxetine potentiates the effect of a low dose of amitriptyline that is ineffective when administered alone. Male and female CD1 mice were administered i.p. 30 min before training, as follows. In the first experiment, they were injected with saline, one of three doses of amitriptyline (2.5, 5, 10mg/kg), one dose of fluoxetine (15 mg/kg), or a combination of amitriptyline (2.5mg/kg) and fluoxetine (15 mg/kg). In the second experiment, the mice were injected with saline, amitriptyline (2.5mg/kg), one of three doses of fluoxetine (10, 15, 20mg/kg), or a combination of 2.5mg/kg of amitriptyline and one of the three mentioned doses of fluoxetine. Drug doses were selected based on previous experiments in our laboratory reported in other publications. The behavioural procedure used to test the effects of these treatments was step-through inhibitory avoidance. The joint administration of amitriptyline 2.5mg/kg and fluoxetine 15 mg/kg had a clear impairing effect on inhibitory avoidance as observed in the two experiments. The dose of 2.5mg/kg of amitriptyline, given alone, was ineffective. Doses of 5mg/kg, or higher, of amitriptyline impaired inhibitory avoidance. The only effect detected when fluoxetine was administered separately was in the males of the experiment 1, which exhibited less avoidance than controls. Our preclinical research throws light on the benefits of the combined administration of antidepressants.

UI MeSH Term Description Entries
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D000639 Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. Amineurin,Amitrip,Amitriptylin Beta,Amitriptylin Desitin,Amitriptylin RPh,Amitriptylin-Neuraxpharm,Amitriptyline Hydrochloride,Amitrol,Anapsique,Apo-Amitriptyline,Damilen,Domical,Elavil,Endep,Laroxyl,Lentizol,Novoprotect,Saroten,Sarotex,Syneudon,Triptafen,Tryptanol,Tryptine,Tryptizol,Amitriptylin Neuraxpharm,Apo Amitriptyline,Desitin, Amitriptylin,RPh, Amitriptylin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D001362 Avoidance Learning A response to a cue that is instrumental in avoiding a noxious experience. Aversion Behavior,Aversion Learning,Aversive Behavior,Aversive Learning,Avoidance Behavior,Aversion Behaviors,Aversive Behaviors,Avoidance Behaviors,Behavior, Aversion,Behavior, Aversive,Behavior, Avoidance,Behaviors, Aversion,Behaviors, Aversive,Behaviors, Avoidance,Learning, Aversion,Learning, Aversive,Learning, Avoidance

Related Publications

Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
April 2005, Behavioural brain research,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
November 2002, Behavioural brain research,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
April 2000, Behavioural brain research,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
December 2009, Behavioural brain research,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
October 1978, Psychopharmacology,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
May 2008, Pharmacology, biochemistry, and behavior,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
October 1988, British journal of clinical pharmacology,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
March 1999, Neurobiology of learning and memory,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
May 1992, The New England journal of medicine,
Andrés Parra, and Aránzazu Ferrer-Añó, and Cristina Fuentes, and Santiago Monleón, and Concepción Vinader-Caerols
July 2002, Neurobiology of learning and memory,
Copied contents to your clipboard!